18 August 2023 - Neurocrine Biosciences today announced the US FDA has approved Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease.

Ingrezza is the only selective vesicular monoamine transporter inhibitor that offers an effective starting dosage that can be adjusted by a patient's healthcare provider based on response and tolerability, with no complex titration.

Read Neurocrine Biosciences press release